Literature DB >> 2934265

Effects of long-term ketoconazole therapy on serum lipid levels.

O Rollman, S Jameson, H Lithell.   

Abstract

Serum cholesterol and triglycerides were determined in 36 patients receiving an 8-month course of oral ketoconazole 200 mg/day in order to study its effect on lipid metabolism. The mean serum cholesterol concentration had decreased by 15% (p less than 0.001) after 1 month, but on continued medication it returned to the pretreatment state; after discontinuation of therapy it increased transiently by 13% (p less than 0.001). Triglycerides increased during ketoconazole administration and at the end of the trial the mean triglyceride concentration was 48% higher than the baseline value (p less than 0.02). Although most lipid values during therapy lay within the normal ranges, 6 patients developed transient hypertriglyceridaemia. There was no correlation between the changes in lipids and peak serum ketoconazole levels. In one subject studied in more detail the concentration of very low density lipoprotein triglycerides rose during therapy, whereas high density lipoprotein cholesterol decreased slightly. The lipoprotein lipase activity in muscle and, in particular, in adipose tissue was significantly suppressed during ketoconazole treatment. Serum lipids and, if possible, serum lipoproteins should be carefully monitored in patients receiving long-term oral ketoconazole therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934265     DOI: 10.1007/bf00547430

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  A METHODOLOGICAL STUDY OF THE ENZYMATIC DETERMINATION OF GLUCOSE IN BLOOD.

Authors:  M HJELM; C H DE VERDIERCH
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  [On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins].

Authors:  M BURSTEIN; J SAMAILLE
Journal:  Clin Chim Acta       Date:  1960-07       Impact factor: 3.786

3.  A method of determining lipoprotein-lipase activity in human adipose tissue.

Authors:  H Lithell; J Boberg
Journal:  Scand J Clin Lab Invest       Date:  1977-10       Impact factor: 1.713

4.  A methodological study of an intravenous fat tolerance test with Intralipid R emulsion.

Authors:  L A Carlson; S Rössner
Journal:  Scand J Clin Lab Invest       Date:  1972-05       Impact factor: 1.713

5.  Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.

Authors:  B Vessby; H Lithell; K Hellsing; A M Ostlund-Lindqvist; I B Gustafsson; J Boberg; H Ledermann
Journal:  Atherosclerosis       Date:  1980-10       Impact factor: 5.162

6.  Ketoconazole blocks testosterone synthesis.

Authors:  A Pont; P L Williams; S Azhar; R E Reitz; C Bochra; E R Smith; D A Stevens
Journal:  Arch Intern Med       Date:  1982-11

7.  Successful treatment of chronic mucocutaneous candidiasis with ketoconazole.

Authors:  H M Rosenblatt; W Byrne; M E Ament; J Graybill; E R Stiehm
Journal:  J Pediatr       Date:  1980-10       Impact factor: 4.406

8.  In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis.

Authors:  H Van den Bossche; G Willemsens; W Cools; F Cornelissen; W F Lauwers; J M van Cutsem
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Ketoconazole inhibits cortisol secretion of an adrenal adenoma in vivo and in vitro.

Authors:  D Engelhardt; K Mann; R Hörmann; S Braun; H J Karl
Journal:  Klin Wochenschr       Date:  1983-04-01

10.  Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins.

Authors:  D S Grosso; T W Boyden; R W Pamenter; D G Johnson; D A Stevens; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

View more
  3 in total

Review 1.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

2.  Inhibition and induction of bile acid synthesis by ketoconazole. Effects on bile formation in the rat.

Authors:  F Kuipers; R Havinga; C M Huijsmans; R J Vonk; H M Princen
Journal:  Lipids       Date:  1989-09       Impact factor: 1.880

3.  Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase.

Authors:  H M Princen; C M Huijsmans; F Kuipers; R J Vonk; H J Kempen
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.